Correlation between levels of sTim-3 and sST2 in peripheral blood and disease severity in patients with alcoholic liver disease

doi:10.11958/20241794

Abstract

Abstract:

Objective To investigate levels of soluble T cell immunoglobulin mucin domain 3 (sTim-3) and soluble growth stimulating gene expression protein 2 (sST2) in peripheral blood of patients with alcoholic liver disease (ALD), and their correlation with disease severity. Methods A total of 112 ALD patients in our hospital from June 2021 to June 2023 were selected as the ALD group, including 47 patients with alcoholic fatty liver (AFL group), 37 patients with alcoholic steatohepatitis (ASH group) and 28 patients with alcoholic liver cirrhosis (ALC group). Another 112 healthy subjects were used as the control group. Enzyme linked immunosorbent assay was applied to detect serum levels of sTim-3 and sST2. ROC curve was used to analyze the diagnostic value of sTim-3 and sST2 in different clinical types of ALD. The correlation between serum sTim-3, sST2 levels and clinical indicators in ALD patients was analyzed by Pearson correlation analysis. The factors influencing disease severity in ALD patients was analyzed by Logistic regression model. Results The serum levels of sTim-3 and sST2 were higher in the ALD group than those in the control group (P<0.05). The serum levels of sTim-3 and sST2 were increased successively in the AFL group, the ASH group and the ALC group (P<0.05). The area under the curve (AUC) of the combined diagnosis of ALC and ASH by sTim-3 and sST2 was significantly larger than that of AUC of the single diagnosis of sTim-3 and sST2 (P<0.05). Levels of glutamic-pyruvic transaminase (ALT), glutamic oxalacetic transaminase (AST), total bilirubin (TBIL), alkaline phosphatase (ALP) and glutamyl transpeptidase (GGT) were increased successively in the AFL group, the ASH group and the ALC group (P<0.05). The serum levels of sTim-3 and sST2 were positively correlated with levels of ALT, AST, TBIL, ALP and GGT, respectively (P<0.05). Logistic regression analysis showed that high levels of sTim-3 and sST2 were independent risk factors for severe disease in ALD patients (P<0.05). Conclusion The serum levels of sTim-3 and sST2 increase in ALD patients, which are related to disease severity in ALD patients.

Key words: liver diseases, alcoholic, fatty liver, alcoholic, liver cirrhosis, alcoholic, hepatitis A virus cellular receptor 2, soluble T cell immunoglobulin mucin domain 3, growth stimulating gene expression protein 2

CLC Number:

R575

Figures/Tables 10

References 30

[1]	李玥, 杨松. 酒精性肝病研究进展[J]. 中国肝脏病杂志(电子版), 2022, 14(3):1-4.
	LI Y, YANG S. Progress on alcoholic liver disease[J]. Chinese Journal of Liver Diseases (Electronic Version), 2022, 14(3):1-4. doi:10.3969/j.issn.1674-7380.2022.03.001.
[2]	AVILA M A, DUFOUR J F, GERBES A L, et al. Recent advances in alcohol-related liver disease (ALD):summary of a Gut round table meeting[J]. Gut, 2020, 69(4):764-780. doi:10.1136/gutjnl-2019-319720.
[3]	SHARMA P, ARORA A. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease:spectrum and diagnosis[J]. Transl Gastroenterol Hepatol, 2020,5:19. doi:10.21037/tgh.2019.10.02.
[4]	CHEN L, YU X, LV C, et al. Increase in serum soluble tim-3 level is related to the progression of diseases after hepatitis virus infection[J]. Front Med (Lausanne), 2022,9:880909. doi:10.3389/fmed.2022.880909.
[5]	HOMSAK E, GRUSON D. Soluble ST2:a complex and diverse role in several diseases[J]. Clin Chim Acta, 2020, 507:75-87. doi:10.1016/j.cca.2020.04.011.
[6]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 实用肝脏病杂志, 2018, 21(2):170-176.
	National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology. Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update[J]. J Prac Hepatol, 2018, 21(2):170-176. doi:10.3969/j.issn.1672-5069.2018.02.006.
[7]	KONG L Z, CHANDIMALI N, HAN Y H, et al. Pathogenesis,early diagnosis,and therapeutic management of alcoholic liver disease[J]. Int J Mol Sci, 2019, 20(11):2712. doi:10.3390/ijms20112712.
[8]	杨孟利, 李三强, 张凯杰, 等. ADAM8的表达对急性酒精性肝损伤小鼠的影响[J]. 天津医药, 2024, 52(4):346-350.
	YANG M L, LI S Q, ZHANG K J, et al. The effect of ADAM8 expression on acute alcoholic liver injury in mice[J]. Tianjin Med J, 2024, 52(4):346-350. doi:10.11958/20231741.
[9]	张飞宇, 赵金明, 阿迪拉·亚克普, 等. 全球酒精性肝病的疾病负担及干预策略[J]. 肝脏, 2021, 26(11):1210-1213.
	ZHANG F Y, ZHAO J M, ADILA Y, et al. Global burden of alcoholic liver disease and intervention strategies[J]. Chinese Hepatology, 2021, 26(11):1210-1213. doi:10.3969/j.issn.1008-1704.2021.11.005.
[10]	张馨元, 陈新梅, 李荣宽. 酒精性肝病诊治研究进展[J]. 中国医师进修杂志, 2023, 46(11):1047-1052.
	ZHANG X Y, CHEN X M, LI R K. Research progress on alcoholic liver disease and gut microbiota[J]. Chin J Postgrad Med, 2023, 46(11):1047-1052. doi:10.3760/cma.j.cn115455-20230301-00196.
[11]	LIU S Y, TSAI I T, HSU Y C. Alcohol-related liver disease:basic mechanisms and clinical perspectives[J]. Int J Mol Sci, 2021, 22(10):5170-5196. doi:10.3390/ijms22105170.
[12]	WU X, FAN X, MIYATA T, et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease[J]. Annu Rev Pathol, 2023,18:411-438. doi:10.1146/annurev-pathmechdis-031521-030435.
[13]	张飞宇, 高沿航. 免疫细胞在酒精性肝病发病机制中的作用及潜在治疗新靶点[J]. 中华肝脏病杂志, 2021, 29(6):510-514.
	ZHANG F Y, GAO Y H. Research update on the role of innate immune cells in the pathogenesis of abdominal aorticaneurysms[J]. Chin J Cardiol, 2021, 29(6):510-514. doi:10.3760/cma.j.cn112148-20220901-00660.
[14]	朱一唯, 闫晓风, 王晓玲, 等. 基于肠道菌群的酒精性肝病发病机制及其治疗研究进展[J]. 肝脏, 2020, 25(6):651-654.
	ZHU Y W, YAN X F, WANG X L, et al. Research progress on pathogenesis and treatment of alcoholic liver disease based on intestinal flora[J]. Chinese Hepatology, 2020, 25(6):651-654. doi:10.3969/j.issn.1008-1704.2020.06.035.
[15]	CARABALLO CORTÉS K, OSUCH S, PERLEJEWSKI K, et al. T-cell exhaustion in HIV-1/hepatitis C virus coinfection is reduced after successful treatment of chronic hepatitis C[J]. Open Forum Infect Dis, 2023, 10(11):ofad514. doi:10.1093/ofid/ofad514.
[16]	刘艳秋, 范海迪, 侯海燕, 等. sTIM-3及其配体Gal-9、HMGB1与2型糖尿病并发冠心病的相关性研究[J]. 天津医药, 2023, 51(3):294-298.
	LIU Y Q, FAN H D, HOU H Y, et al. Correlation research between sTIM-3 and its ligands Gal-9,HMGB1 in patients with type 2 diabetes complicated with coronary heart disease[J]. Tianjin Med J, 2023, 51(3):294-298. doi:10.11958/20221307.
[17]	YUAN L, WANG Y, SHEN X, et al. Soluble form of immune checkpoints in autoimmune diseases[J]. J Autoimmun, 2024,147:103278. doi:10.1016/j.jaut.2024.103278.
[18]	MIGITA K, NAKAMURA M, AIBA Y, et al. Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis[J]. PLoS One, 2020, 15(12):e0238540. doi:10.1371/journal.pone.0238540.
[19]	WU S, DU X, LOU G, et al. Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection[J]. BMC Infect Dis, 2022, 22(1):842. doi:10.1186/s12879-022-07841-1.
[20]	FADRIQUELA A, KIM C S, LEE K J, et al. Characteristics of immune checkpoint regulators and potential role of soluble TIM-3 and LAG-3 in male patients with alcohol-associated liver disease[J]. Alcohol, 2022, 98:9-17. doi:10.1016/j.alcohol.2021.
[21]	CHEN P K, HSU W F, PENG C Y, et al. Significant association of elevated serum galectin-9 levels with the development of non-alcoholic fatty liver disease in patients with rheumatoid arthritis[J]. Front Med (Lausanne), 2024,11:1347268. doi:10.3389/fmed.2024.1347268.
[22]	GUO H, BOSSILA E A, MA X, et al. Dual immune regulatory roles of interleukin-33 in pathological conditions[J]. Cells, 2022, 11(20):3237. doi:10.3390/cells11203237.
[23]	HILDENBRAND F F, ILLI B, VON FELTEN S, et al. Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis[J]. BMC Gastroenterol, 2024, 24(1):54. doi:10.1186/s12876-023-03116-4.
[24]	CHEN S, WU L, PENG L, et al. Hepatitis B virus X protein (HBx) promotes ST2 expression by GATA2 in liver cells[J]. Mol Immunol, 2020, 123:32-39. doi:10.1016/j.molimm.2020.04.024.
[25]	ARTRU F, BOU SALEH M, MAGGIOTTO F, et al. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis[J]. J Hepatol, 2020, 72(6):1052-1061. doi:10.1016/j.jhep.2019.12.017.
[26]	胡瑞华. 血清可溶性生长刺激表达基因2蛋白与慢加急性乙型肝炎肝衰竭的严重程度及预后的相关性[J]. 河南医学研究, 2021, 30(30):5673-5676.
	HU R H. Correlation between the level of serum soluble growth stimulating expressed gene 2 protein and the severity and prognosis of acute-on-chronic hepatitis B liver failure[J]. Henan Medical Research, 2021, 30(30):5673-5676. doi:10.3969/j.issn.1004-437X.2021.30.034.
[27]	张春玲, 邱春玉, 徐恩松. 可溶性生长刺激表达基因2蛋白对老年转移性肝细胞癌的诊断效能[J]. 中国老年学杂志, 2022, 42(11):2676-2678.
	ZHANG C L, QIU C Y, XU E S. Diagnostic efficacy of soluble growth stimulation gene 2 protein in elderly patients with metastatic hepatocellular carcinoma[J]. Chinese Journal of Gerontology, 2022, 42(11):2676-2678. doi:10.3969/j.issn.1005-9202.2022.11.022.
[28]	SUN Z, CHANG B, HUANG A, et al. Plasma levels of soluble ST2,but not IL-33,correlate with the severity of alcoholic liver disease[J]. J Cell Mol Med, 2019, 23(2):887-897. doi:10.1111/jcmm.13990.
[29]	MOON H W, PARK M, HUR M, et al. Usefulness of enhanced liver fibrosis,glycosylation isomer of Mac-2 binding protein,Galectin-3 and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases[J]. Ann Lab Med, 2018, 38(4):331-337. doi:10.3343/alm.2018.38.4.331.
[30]	冯宇, 杜振元, 李艳彬, 等. 酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析[J]. 实用肝脏病杂志, 2022, 25(1):58-61.
	FENG Y, DU Z Y, LI Y B, et al. Serum IL-17 levels and single nucleotide polymorphism of its gene at -197A/G locus in patients with alcoholic liver diseases[J]. J Prac Hepatol, 2022, 25(1):58-61. doi:10.3969/j.issn.1672-5069.2022.01.015.

组别	sTim-3/（μg/L）	sST2/（ng/L）
对照组	1.69±0.57	13.06±3.15
ALD组	7.02±0.76	62.58±6.37
t	59.802^＊＊	73.727^＊＊

组别	sTim-3/（μg/L）	sST2/（ng/L）
对照组	1.69±0.57	13.06±3.15
ALD组	7.02±0.76	62.58±6.37
t	59.802^＊＊	73.727^＊＊

组别	n	sTim-3/（μg/L）	sST2/（ng/L）
AFL组	47	6.56±0.76	58.53±5.48
ASH组	37	7.15±0.73^a	63.60±5.89^a
ALC组	28	7.62±0.81^ab	68.02±6.46^ab
F		17.732^＊＊	23.761^＊＊

组别	n	sTim-3/（μg/L）	sST2/（ng/L）
AFL组	47	6.56±0.76	58.53±5.48
ASH组	37	7.15±0.73^a	63.60±5.89^a
ALC组	28	7.62±0.81^ab	68.02±6.46^ab
F		17.732^＊＊	23.761^＊＊

指标	截断值	AUC	95%CI	敏感度	特异度	约登指数
sTim-3	7.37 μg/L	0.738	0.647~0.817	0.714	0.821	0.536
sST2	64.96 ng/L	0.756	0.666~0.833	0.786	0.845	0.631
二者联合		0.870	0.794~0.926	0.893	0.810	0.702